UK biotech venture capital funding hits record high in Q2 2026, surpassing any full year since 2022
read at Endpoints ↗DealPositive
UK biotech companies secured more venture capital in the second quarter of 2026 than they did in any full calendar year since 2022.
The surge reflects a broader fundraising revival, with investors drawn to the sector’s pipeline and growth prospects.
Analysts view the inflow as a positive signal for the UK’s biotech ecosystem, potentially supporting new drug development and collaborations.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “UK biotech VC funding rebounds and reaches record high”
read at Endpoints ↗80 words · retrieved Jul 20
comments(0)
5-min edit window · permanent after that